Viewing Opinion | StockChase
AbbVie Inc. (ABBV-N) opinion on 2017-04-20

Last Price Recorded: 94.6800 on 2017-11-21

ON STOCKCHASE SINCE Jan 2013

0
PAST TOP PICK

Lorne Zeiler
AbbVie Inc. was $63.780 at time of opinion
Owned : Yes

(A Top Pick Dec 23/16. Up 4%.) A one trick pony with their drug Humira. Valuation is quite reasonable and is going to be 12-13X projected earnings. A lot of that is based on sales of Humira, a life altering drug, which accounts for over 60% of their revenues. Made 2 very large acquisitions in the past few years, and we are starting to see some of those drugs in the pipeline getting approved.

UNKNOWN

All opinions for ABBV-N (27)

1 BUY
5 COMMENT
3 DON'T BUY
1 HOLD
7 PAST TOP PICK
2 SELL
8 TOP PICK
View All

More experts covering ABBV-N

SAVE
Add ABBV-N to Watch List

All opinions for ABBV-N (27)

1 BUY
5 COMMENT
3 DON'T BUY
1 HOLD
7 PAST TOP PICK
2 SELL
8 TOP PICK
View All

More experts covering ABBV-N

SAVE
Add ABBV-N to Watch List

No Comments.


You must be logged in to comment.

Successfully Saved Company